Appendix C- Methodology and references for eligible treatment populations

Renal cell carcinoma
85% of kidney cancers

Clear cell carcinoma – 75-80% of kidney cancer. Average 77.5%

Nonclear cell carcinoma – 20-25% of kidney cancer. Average 22.5%

Advanced/metastatic – 71.5%\(^2\) [NICE guidance states 26% and 17% have stage III and IV disease, and about half of those with curative resection for earlier stages of the disease also go on to develop advanced and/or metastatic disease. Calculation 26+17+(0.5\times57) = 71.5%]

Breast cancer

Metastatic breast cancer at presentation 5%, with 35% who present with local breast cancer who will progress. Total 38.25%\(^3\)

20-30% with metastatic breast cancer are HER2+, of which 50% will also be hormone receptor positive\(^4\)

Average 12.5%

Chronic Myeloid Leukaemia
12.3% of Leukaemia (C91-95)\(^5\)

Philadelphia chromosome positive 85-90%\(^6\)

Acute Lymphoblastic Leukaemia
11.5% of Leukaemia (C91-95)\(^5\)

Philadelphia chromosome positive 25%\(^7\)

References


oestrogen-receptor-positive-locally-advanced-or-metastatic-everolimus-with-an-aromatase-inhibitor-afinitor2


